<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009134</url>
  </required_header>
  <id_info>
    <org_study_id>ENT-ALLERGY-01</org_study_id>
    <nct_id>NCT05009134</nct_id>
  </id_info>
  <brief_title>Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination</brief_title>
  <official_title>Influences of Allergic Rhinitis and Allergen Immunotherapy on Human Antibody Responses to SARS-CoV-2 Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to assess whether allergic rhinitis and allergen immunotherapy affect&#xD;
      the humoral response to SARS-CoV-2 Vaccination in adults. This is a prospective study&#xD;
      enrolling a total of approximately 120 subjects, 18-55 years old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Allergic rhinitis (AR) is a disorder caused by hypersensitivity of the immune&#xD;
      system to harmless allergens in the environment, which represents a global public health&#xD;
      problem affecting up to 20-50% of the population. Allergen immunotherapy (AIT) is the only&#xD;
      effective treatment that not only has disease-modifying property but also confers long-term&#xD;
      clinical benefit after cessation of treatment for AR patients. Vaccination is one of the most&#xD;
      powerful interventions for reducing disability and death caused by infectious disease.&#xD;
      Immunization with the inactivated SARS-CoV-2 Vaccine remains the most effective strategy to&#xD;
      combat COVID-19 infections. Nevertheless, the influences of allergic rhinitis and allergen&#xD;
      immunotherapy on SARS-CoV-2 vaccination are still unknown.&#xD;
&#xD;
      Objectives: To investigate if AR and AIT will influence the humoral response to SARS-CoV-2&#xD;
      vaccination in adults.&#xD;
&#xD;
      Design and trial size: This is a prospective study. A total of approximately 120 subjects,&#xD;
      18-55 years old, including 40 healthy subjects, 40 patients with AR without AIT, and 40&#xD;
      patients with AR with AIT for more than 1 year, will be enrolled in this study.&#xD;
&#xD;
      Intervention and duration: All of the study participants will be vaccinated with an 2 doses&#xD;
      inactivated vaccine against SARS-CoV-2 (COVILO). Peripheral blood samples will be collected&#xD;
      at baseline (prior to vaccinate), 7 and 30 after first vaccine, and, 7 and 30 after second&#xD;
      vaccine. One-month additional data analysis leads to the trial duration of 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Virus-specific antibodies levels in serum and humoral immune response as measured by ELISA or HAI assay</measure>
    <time_frame>Jun 2021-Aug 2021</time_frame>
    <description>Virus-specific antibodies levels in serum and humoral immune response as measured by ELISA or HAI assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequencies and numbers of circulating T cell subsets, B cell subsets, dendritic cells, NK cells in peripheral blood</measure>
    <time_frame>Jun 2021-Aug 2021</time_frame>
    <description>Frequencies and numbers of circulating T cell subsets, B cell subsets, dendritic cells, NK cells in peripheral blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of antigen-specific IgE and IgG4, IFN-γ, IL-4, IL-5, IL-10, IL-17A, and IL-21 in serum detected by ELISA</measure>
    <time_frame>Jun 2021-Aug 2021</time_frame>
    <description>Levels of antigen-specific IgE and IgG4, IFN-γ, IL-4, IL-5, IL-10, IL-17A, and IL-21 in serum detected by ELISA</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Allergen Immunotherapy</condition>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>18-55 years, healthy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergic rhinitis</arm_group_label>
    <description>patients with AR without AIT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergen immunotherapy</arm_group_label>
    <description>patients with AR with AIT for more than 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>There is no intervention in this study.</intervention_name>
    <description>There is no intervention in this study.</description>
    <arm_group_label>Allergen immunotherapy</arm_group_label>
    <arm_group_label>Allergic rhinitis</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples will be collected at baseline (prior to vaccinate), 7 and 30 after&#xD;
      first vaccine, and, 7 and 30 after second vaccine.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        18-55 years; healthy subjects, patients with AR without AIT, or patients with AR with AIT&#xD;
        for more than 1 year&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        18-55 years; healthy subjects, patients with AR without AIT, or patients with AR with AIT&#xD;
        for more than 1 year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. who infected with COVID-19 previously&#xD;
&#xD;
          2. Cannot finish the follow up&#xD;
&#xD;
          3. Previous allergic to other vaccines&#xD;
&#xD;
          4. who have had severe immunologic, cardiac, liver or metabolic disease, tumors, allergic&#xD;
             diseases, or chronic infection,&#xD;
&#xD;
          5. pregnancy or breastfeeding&#xD;
&#xD;
          6. Suffered from airway infection or severe infectious diseases in the past 3 months,&#xD;
             prior to this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Zheng Liu, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Liu, Doctor</last_name>
    <phone>86 027 83663807</phone>
    <email>zhengliuent@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong-Fei Zhu, Doctor</last_name>
    <email>zrf13092@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Liu, Doctor</last_name>
      <phone>86 027 83663807</phone>
      <email>zhengliuent@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rong-Fei Zhu, Doctor</last_name>
      <phone>86 027 83663809</phone>
      <email>zrf13092@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zheng Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong-Fei Zhu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Zheng Liu</investigator_full_name>
    <investigator_title>Professor of Otolaryngology-Head &amp; Neck Surgery, Deputy Dean of Tongji Hospital, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

